381.02  0 (0%)		12-21 16:00
Open: 380.78 High: 381.28 Volume: 15,702,662		Pre. Close: 381.02 Low: 380.545 Market Cap: 17,181(M)

Short term
Mid term
Targets	6-month :	445.94	1-year :	520.86
Resists	First :	381.79	Second :	445.94
Pivot price	380.33
Supports	First :	378.24	Second :	376.04
MAs	MA(5) :	380.97	MA(20) :	379.64
	MA(100) :	308.19	MA(250) :	294.47
MACD	MACD :	6.8	Signal :	9.2
%K %D	K(14,3) :	84.4	D(3) :	84.3
RSI	RSI(14): 76.2
52-week	High :	381.98	Low :	219.84

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ABMD ] has closed below upper band by 33.4%. Bollinger Bands are 91.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	382.17 - 384.05	384.05 - 385.58
Low:	375.22 - 377.84	377.84 - 379.96
Close:	377.39 - 381.32	381.32 - 384.5

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Fri, 19 Apr 2024
ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing? - Yahoo Lifestyle Australia

Thu, 22 Dec 2022
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio - Yahoo Finance

Thu, 22 Dec 2022
Johnson & Johnson completes Abiomed acquisition - Mass Device

Wed, 21 Dec 2022
A Look At Abiomed Before The $380/Share Buyout From JNJ (ABMD) - Seeking Alpha

Tue, 01 Nov 2022
Johnson & Johnson to Acquire Abiomed - Business Wire

Tue, 01 Nov 2022
Heart Pump Stock's Wild Ride Ends With $17 Billion J&J Takeover - Bloomberg

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	45 (M)
Shares Float	44 (M)
Held by Insiders	2 (%)
Held by Institutions	97 (%)
Shares Short	754 (K)
Shares Short P.Month	2,080 (K)

EPS	5.82
EPS Est Next Qtrly	0.56
EPS Est This Year	2.32
EPS Est Next Year	2.67
Book Value (p.s.)	34.09
Profit Margin	24.8 %
Operating Margin	22.9 %
Return on Assets (ttm)	9.5 %
Return on Equity (ttm)	18.2 %
Qtrly Rev. Growth	7.1 %
Gross Profit (p.s.)	18.7
Sales Per Share	23.73
EBITDA (p.s.)	6.08
Qtrly Earnings Growth	87 %
Operating Cash Flow	251 (M)
Levered Free Cash Flow	202 (M)

PE Ratio	65.35
PEG Ratio	5.2
Price to Book value	11.17
Price to Sales	16.05
Price to Cash Flow	68.45

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.